Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Hostettler, E. Papakonstantinou, I. Klagas, G. Karakiulakis, M. Tamm, D. Lardinois, M. Roth (Basel, Switzerland; Thessaloniki, Greece). Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: Suppl. 56, 3161

Member's Comments

No comment yet.

Related content which might interest you: Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Antifibrosic effects of sulforaphane in human lung fibroblasts from idiopathic pulmonary fibrosis Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 The effect of nintedanib compared to pirfenidone on proliferation of lung fibroblasts from patients with IPF Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Therapeutic pamrevlumab (FG-3019) is more effective than pirfenidone or nintedanib in a mouse radiation-induced lung fibrosis model Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 LATE-BREAKING ABSTRACT: Anti-fibrotic effects of nintedanib and pirfenidone in 2D versus 3D lung cultures Source: International Congress 2016 – IPF pathogenesis Year: 2016 Changes in biomarkers in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Arsenic trioxyde inhibits the functions on lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis (IPF): the INSTAGE trial Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias Year: 2018 The long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Effects of nintedanib in patients with systemic sclerosis-associated ILD (SSc-ILD) and differing extents of lung fibrosis: the SENSCIS trial Source: International Congress 2019 – From biomarkers to treatment of immune-mediated interstitial lung disease: what’s new? Year: 2019 Antifibrotics effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing intertitial lung diseases Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019